- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01532882
Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs (EDEN)
Assessment of the Efficacy and Safety of Diosmin 600mg on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs: a Multicentric, Randomised, Double-blind, Placebo-controlled Trial in Parallel Groups
Diosmin has a well established use status in improvement of the symptoms of venolymphatic insufficiency: heavy legs, pain, primo-decubitus restlessness and as complement treatment of capillary fragility.
Nevertheless, diosmin 600 mg did not benefit from a rigorous clinical study versus placebo, to establish its efficacy in the pain relief in Chronic Venous Disease (CVD).
The aim of this project led by Dr. Guex is to evaluate the efficacy and safety of diosmin 600 mg - DIOVENOR® on the painful symptoms of CVD of the lower limbs, in a multicentre, controlled, randomised, double blind, placebo-controlled, parallel-group study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Nice, France, 06000
- Dr Jean-Jérôme GUEX
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient, man or woman, aged 18 and over,
- Patient presenting a C1s or C2s venous disease grade of the lower limbs
- Patient presenting a painful venous symptomatology in the lower limbs for at least 15 days.
- Patient suffering from venous symptomatology in one leg with a painful symptom intensity higher or equal to 30 mm (VAS= 100mm)
Exclusion Criteria:
- Patient treated by venotonic treatments or vascular protectants or assimilated dietary supplements or homeopathic treatments or diuretics within 15 days prior inclusion,
- Patients who started treatments such as calcium inhibitors, beta-blockers, angiotensin converting enzyme inhibitors and/or vasodilators and/or vasoconstrictors within 28 days prior inclusion (for patients already taking this type of treatments, dosage should not have been changed in the 28 days prior inclusion and should not be planned to change in the course of the study),
- Patient treated by any analgesic within 7 days prior inclusion,
- Patient treated by an anti-inflammatory treatment within 7 days prior inclusion,
- Patient using elastic venous compression
- Patient presenting permanent oedema,
- Patients presenting venous skin changes,
- Patient whose activity in the 4 following weeks (that is to say during the study) would be different from his/her usual activities (before the study),
- Patient suffering from a pathology generating other pains than venous pains in the lower limbs,
- Patient with a history of lower limbs trauma responsible for sequel pains,
- Patient with a known deep venous reflux,
- Patient with a history of venous thromboses or thrombo-embolic diseases within the last 6 months before inclusion,
- Patient treated with analgesics or anti-inflammatory treatments used as analgesics within 4 weeks prior inclusion
- Patient having a known hypersensitivity to diosmin or one of the excipients
- Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption ),
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
tablet, PO, 1 per day during 28 days
|
Experimental: Diosmin
|
tablet, 600mg, PO, 1 tab per day during 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of Visual analog Scale score for assessment of the painful venous symptomatology
Time Frame: baseline and after 28 days
|
baseline and after 28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
- Painful symptom intensity (daily VAS score) Area Under the Curve
Time Frame: 28 days
|
28 days
|
- Daily VAS score for Response rate
Time Frame: 28 days
|
28 days
|
- Daily VAS score for Time to response
Time Frame: 28 days
|
28 days
|
- Score of Quality of life questionnaire (SQOR-V)
Time Frame: Between baseline and 28 days
|
Between baseline and 28 days
|
- Patient's and physician's global satisfaction score
Time Frame: At 28 days
|
At 28 days
|
Adverse Events (numbers and frequency)
Time Frame: 28 days
|
28 days
|
- Unusual intakes of analgesic treatments (rate of patients)
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jean-Jérôme GUEX, MD
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- DIO401-10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Venous Disease of Lower Limbs
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingChildhood Malignant Tumors of Lower LimbsFrance
-
University Hospital, AngersUnknownObliterating Arteriopathy of the Lower LimbsFrance
-
Central Hospital, Nancy, FranceUniversity of Lorraine; Centre National de la Recherche Scientifique, FranceNot yet recruitingClinical Evaluation of an Innovative Non-contact Optical Device for Skin Oxygenation Imaging (IMOXY)Obliterating Arteriopathy of the Lower Limbs | Chronic WoundsFrance
-
Instituto de Investigación Hospital Universitario...Hospital Universitario La PazCompletedNonrevascularizable Critical Ischemia of the Lower LimbsSpain
-
Universidade Federal de Sao CarlosCompletedHealthy Young Male Volunteers | Non Athletes | Free of Metabolic Disease | Joint, Bone and Muscles of Lower Limbs Free of Any DiseaseBrazil
-
University of Sao PauloCompletedVaricose Vein of Lower Limbs
-
Abbott Medical DevicesCompletedChronic, Intractable Pain of the Trunk and/or Lower LimbsUnited States, Australia, Netherlands, Sweden, Germany, Italy, Austria
-
Pirogov Russian National Research Medical UniversityEnrolling by invitationVaricose Veins of Lower Limb | Chronic Venous InsufficiencyRussian Federation
-
Foundation IRCCS San Matteo HospitalActive, not recruitingGreater Trochanteric Pain Syndrome of Both Lower LimbsItaly
-
Inari MedicalActive, not recruitingDVT | Deep Vein Thrombosis Leg | Chronic DVT of Lower Extremity | Acute DVT of Lower ExtremityUnited States
Clinical Trials on Diosmin
-
Tanta UniversityRecruitingNon-bleeding Peptic UlcerEgypt
-
Fundação Educacional Serra dos ÓrgãosCompleted
-
Tanta UniversityRecruitingNon Alcoholic SteatohepatitisEgypt
-
Vidfarma Indústria de Medicamentos Ltda.UnknownHemorrhoids | Chronic Venous InsufficiencyBrazil
-
Primus PharmaceuticalsKGK Science Inc.Not yet recruitingScleroderma, Systemic | Digital Ulcer
-
Giellepi S.p.AOpera CRO, a TIGERMED Group CompanyNot yet recruiting
-
Primus PharmaceuticalsWithdrawnDiabetic UlcersUnited States
-
Laboratorios Andromaco S.A.Completed
-
Laboratório Teuto Brasileiro S/AUnknownDisease | Chronic Venous Insufficiency
-
Pirogov Russian National Research Medical UniversityCompletedVaricose VeinsRussian Federation